Yang Guo-Wei, Zhao Qing, Qian Sheng, Zhu Liang, Qu Xu-Dong, Zhang Wei, Yan Zhi-Ping, Cheng Jie-Min, Liu Qing-Xin, Liu Rong, Wang Jian-Hua
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Onco Targets Ther. 2015 May 26;8:1245-50. doi: 10.2147/OTT.S84764. eCollection 2015.
To retrospectively evaluate the safety and efficacy of ultrasound-guided percutaneous microwave ablation (MWA) combined with simultaneous transarterial chemoembolization (TACE) in the treatment of patients with advanced intrahepatic cholangiocarcinoma (ICC).
All patients treated with ultrasound-guided percutaneous MWA combined with simultaneous TACE for advanced ICC at our institution were included. Posttreatment contrast-enhanced computed tomography and/or magnetic resonance imaging were retrieved and reviewed for tumor response to the treatment. Routine laboratory studies, including hematology and liver function tests were collected and analyzed. Procedure-related complications were reviewed and survival rates were analyzed.
From January 2011 to December 2014, a total of 26 advanced ICC patients were treated at our single institute with ultrasound-guided percutaneous MWA combined with simultaneous TACE. There were 15 males and eleven females with an average age of 57.9±10.4 years (range, 43-75 years). Of 26 patients, 20 (76.9%) patients were newly diagnosed advanced ICC without any treatment, and six (23.1%) were recurrent and treated with surgical resection of the original tumor. The complete ablation rate was 92.3% (36/39 lesions) for advanced ICC. There were no major complications observed. There was no death directly from the treatment. Median progression-free survival and overall survival were 6.2 and 19.5 months, respectively. The 6-, 12-, and 24-month survival rates were 88.5%, 69.2%, and 61.5%, respectively.
The study suggests that ultrasound-guided percutaneous MWA combined with simultaneous TACE therapy can be performed safely in all patients with advanced ICC. The complete ablation rate was high and there was no major complication. The overall 24-month survival was 61.5%.
回顾性评估超声引导下经皮微波消融（MWA）联合同期经动脉化疗栓塞术（TACE）治疗晚期肝内胆管癌（ICC）患者的安全性和疗效。
纳入在本机构接受超声引导下经皮MWA联合同期TACE治疗晚期ICC的所有患者。检索并回顾治疗后对比增强计算机断层扫描和/或磁共振成像，以评估肿瘤对治疗的反应。收集并分析包括血液学和肝功能检查在内的常规实验室研究结果。回顾与手术相关的并发症并分析生存率。
2011年1月至2014年12月，本单中心共26例晚期ICC患者接受了超声引导下经皮MWA联合同期TACE治疗。其中男性15例，女性11例，平均年龄57.9±10.4岁（范围43 - 75岁）。26例患者中，20例（76.9%）为新诊断的晚期ICC，未接受过任何治疗，6例（23.1%）为复发患者，接受过原发肿瘤手术切除。晚期ICC的完全消融率为92.3%（36/39个病灶）。未观察到严重并发症。无直接因治疗导致的死亡。无进展生存期和总生存期的中位数分别为6.2个月和19.5个月。6个月、12个月和24个月的生存率分别为88.5%、69.2%和61.5%。
该研究表明，超声引导下经皮MWA联合同期TACE治疗对所有晚期ICC患者均安全可行。完全消融率高，无严重并发症。24个月总生存率为61.5%。
